NASDAQ
Coherus Oncology, Inc. (CHRS) has a revenue compound annual growth rate of -38.41% over 5 years and 3.45% over 10 years. Revenue CAGR shows the compound annual growth rate of a company's total sales, indicating the pace of top-line expansion.
No price data available for this timeframe.